GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Achillion Pharmaceuticals, Inc. (ACHN) [hlAlert]

Rating:
Neutral ACHN
up 66.74 %

Achillion Pharmaceuticals, Inc. (ACHN) downgraded to Neutral with price target $16 by Robert W. Baird

Posted on: Tuesday,  Dec 23, 2014  8:25 AM ET by Robert W. Baird

Robert W. Baird rated Neutral Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) on 12/23/2014. Previously Robert W. Baird rated Outperform Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)
on 01/04/2013., when the stock price was $8.96. Since then, Achillion Pharmaceuticals, Inc. has gained 66.74% as of 12/23/2014's recent price of $14.94.
If you would have followed the previous Robert W. Baird's recommendation on ACHN, you would have gained 66.74% of your investment in 718 days.

Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. It has a pipeline of other product candidates, for which it is seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of human immunodeficiency virus (HIV) infection and ACH-702 for the treatment of serious bacterial infections.

Deep, comprehensive coverage is essential to your success. And with nearly 100 research professionals covering over 500 U.S. companies, our reputation for trusted, award-winning, in-depth analysis with a strong commitment to objective, fundamental research speaks for itself.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/23/2014 8:25 AM Hold
None
14.94 16.00
as of 10/17/2014
1 Week up  10.80 %
1 Month down  -8.20 %
3 Months up  64.96 %
1 YTD up  230.42 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/4/2013 8:25 AM Buy
None
8.96 17.00
8/25/2011 8:25 AM Buy
None
5.70 9.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy